drugset / Trial / NCT02333890

A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer

NCT02333890

Phase 2 Unknown 60 enrolled Ottawa Hospital Research Institute
RandomizedParallel-groupTriple-blindTreatment

Summary

Chloroquine (CQ) is a well known, well tolerated medication that has been used for many years traditionally for arthritis, lupus, and malaria. It has anti-inflammatory properties but is often the drug of choice for arthritis and malaria due to its few side effects. Recently, laboratory investigations have proven that CQ may potentially have anti-cancer properties, by inhibiting a process which allows cancers such as breast cancer to continue to grow (a process known as "autophagy"). Therefore, this study will look at how well CQ can inhibit the growth of breast cancers in patients while waiting for surgery.

Timeline

Start
2015-07
Primary completion
2017-03
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloroquine Small molecule 500 mg Oral